<?xml version="1.0" encoding="UTF-8"?>
<ref id="B172-pharmaceutics-12-00688">
 <label>172.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Steinestel</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Eder</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ehinger</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Schneider</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Genze</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Winkler</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Wardelmann</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Schrader</surname>
    <given-names>A.J.</given-names>
   </name>
   <name>
    <surname>Steinestel</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells</article-title>
  <source>Tumor Biol.</source>
  <year>2016</year>
  <volume>37</volume>
  <fpage>6275</fpage>
  <lpage>6283</lpage>
  <pub-id pub-id-type="doi">10.1007/s13277-015-4509-5</pub-id>
 </element-citation>
</ref>
